Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xilio Therapeutics (XLO) Notes Payables (2023)

Xilio Therapeutics' Notes Payables history spans 1 years, with the latest figure at $3.3 million for Q4 2023.

  • On a quarterly basis, Notes Payables changed N/A to $3.3 million in Q4 2023 year-over-year; TTM through Dec 2023 was $3.3 million, a N/A change, with the full-year FY2023 number at $3.3 million, changed N/A from a year prior.
  • Notes Payables hit $3.3 million in Q4 2023 for Xilio Therapeutics.
  • Over the last five years, Notes Payables for XLO hit a ceiling of $3.3 million in Q4 2023 and a floor of $3.3 million in Q4 2023.